

4.0.03 DOC Cmte minutes

Thyroid cancer Committee meeting 6

Date: 27/04/21 10:00-16:00

Location: Virtual meeting

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:	
Richard Grünewald [RG] – Chair	(Present for notes 1 – 6)
Jeremy Davis [JD] – Topic advisor	(Present for notes 1 – 6)
John Buscombe [JB]	(Present for notes 1 – 6)
Preetha Chengot [PC]	(Present for notes 1 – 6)
Neil Cozens [NC]	(Present for notes 1 – 6)
Fiona Eatock [FE]	(Present for notes 1 – 6)
Steve Hyer [SH]	(Present for notes 1 – 6)
Jessica Lishak [JL]	(Present for notes 1 – 6)
Kate Newbold [KN]	(Present for notes 1 – 6)
Sonja Hoy [SH]	(Present for notes 1 – 6)
Iain Nixon [IN]	(Present for notes 1 – 6)
Anh Tran [AT]	(Present for notes 1 – 6)

In attendance:		
Catrina Charlton [CC]	NICE Guideline Commissioning Manager	(Present for notes 1 – 6)
Carlos Sharpin [CS]	Guideline Lead	(Present for notes 1 – 6)
Mark Perry [MP]	Senior Research Fellow	(Present for notes 1 – 6)
Alfredo Mariani [AM]	Health Economist	(Present for notes 1 – 6)
Kevin Galbraith [KG]	Research Fellow	(Present for notes 1 – 6)

Apologies:	
Kate Farnell [KF]	GC member
Giulia Zuodar [GZ]	Project Manager
Lina Gulhane [LG]	Head of Information Specialists

4.0.03 DOC Cmte minutes

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the sixth meeting on Thyroid cancer. The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included:

- discussing the review on RAI activity / dose after thyroidectomy
- discussing the review on Active surveillance vs hemi-thyroidectomy vs total thyroidectomy
- discussing protocols on:
 - Follow up
 - Indications for blood tests
 - Threshold of size and US characteristics for active surveillance
 - Preventing risk of recurrence
 - Measuring thyroglobulin

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was RAI activity / dose after thyroidectomy, Active surveillance vs hemi-thyroidectomy vs total thyroidectomy, Follow up, Indications for blood tests, Threshold of size and US characteristics for active surveillance, Preventing risk of recurrence, Measuring thyroglobulin.

The following declarations were received:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
NC	GC member	I have joined the UK guidelines for management of thyroid cancer committee	Direct, non-financial, professional and personal	Specific. The guideline will be produced collaboratively by consensus. Declare and participate
KF	GC member	Producing information for hospital nuclear medicine	Direct, non-financial,	Non-specific

4.0.03 DOC Cmte minutes

		Dept's, wards and patients on information patients are given on restrictions post RAI treatment	professional and personal	Declare and participate
SH	GC member	Asked to update the Macmillan patient information leaflet on Thyroid cancer	Direct, non-financial, professional and personal	Non-specific Declare and participate
<p>The Chair and a senior member of the Developer's team noted that the interests previously declared did not prevent the attendees from fully participating in the meeting.</p>				
<p>3. Evidence review: RAI activity / dose after RAI activity / dose after thyroidectomy</p>				
<p>MP/AM presented the evidence for RAI activity / dose after RAI activity / dose after thyroidectomy. The GC drafted recommendations.</p>				
<p>4. Evidence review: Active surveillance vs hemi-thyroidectomy vs total thyroidectomy</p>				
<p>KG/AM presented the evidence for Active surveillance vs hemi-thyroidectomy vs total thyroidectomy. The GC drafted recommendations.</p>				
<p>5. Draft protocols</p>				
<p>MP presented draft protocols:</p> <ul style="list-style-type: none"> • Follow up • Indications for blood tests • Threshold of size and US characteristics for active surveillance <p>Preventing risk of recurrence and Measuring thyroglobulin will be discussed at the next meeting.</p>				
<p>6 Any other business</p>				
<p>None.</p>				

Date of next meeting:

26 May 2021

4.0.03 DOC Cmte minutes

Location of next meeting: Virtual meeting